Skip to main content

Main menu

  • Home
  • Current issue
  • ERJ Early View
  • Past issues
  • ERS Guidelines
  • Authors/reviewers
    • Instructions for authors
    • Submit a manuscript
    • Open access
    • Peer reviewer login
  • Alerts
  • Subscriptions
  • ERS Publications
    • European Respiratory Journal
    • ERJ Open Research
    • European Respiratory Review
    • Breathe
    • ERS Books
    • ERS publications home

User menu

  • Log in
  • Subscribe
  • Contact Us
  • My Cart

Search

  • Advanced search
  • ERS Publications
    • European Respiratory Journal
    • ERJ Open Research
    • European Respiratory Review
    • Breathe
    • ERS Books
    • ERS publications home

Login

European Respiratory Society

Advanced Search

  • Home
  • Current issue
  • ERJ Early View
  • Past issues
  • ERS Guidelines
  • Authors/reviewers
    • Instructions for authors
    • Submit a manuscript
    • Open access
    • Peer reviewer login
  • Alerts
  • Subscriptions

Aspergillus fumigatus during stable state and exacerbations of COPD

Mona Bafadhel, Susan Mckenna, Joshua Agbetile, Abbie Fairs, Dhananjay Desai, Vijay Mistry, Joseph P. Morley, Mitesh Pancholi, Ian D. Pavord, Andrew J. Wardlaw, Catherine H. Pashley, Christopher E. Brightling
European Respiratory Journal 2014 43: 64-71; DOI: 10.1183/09031936.00162912
Mona Bafadhel
1Dept of Respiratory Medicine, Nuffield Department of Medicine, University of Oxford, Oxford
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: mona.bafadhel@ndm.ox.ac.uk
Susan Mckenna
2Dept of Infection, Immunity and Inflammation, Institute for Lung Health, NIHR Respiratory Biomedical Research Unit, University of Leicester, Leicester, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Joshua Agbetile
2Dept of Infection, Immunity and Inflammation, Institute for Lung Health, NIHR Respiratory Biomedical Research Unit, University of Leicester, Leicester, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Abbie Fairs
2Dept of Infection, Immunity and Inflammation, Institute for Lung Health, NIHR Respiratory Biomedical Research Unit, University of Leicester, Leicester, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Dhananjay Desai
2Dept of Infection, Immunity and Inflammation, Institute for Lung Health, NIHR Respiratory Biomedical Research Unit, University of Leicester, Leicester, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Vijay Mistry
2Dept of Infection, Immunity and Inflammation, Institute for Lung Health, NIHR Respiratory Biomedical Research Unit, University of Leicester, Leicester, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Joseph P. Morley
2Dept of Infection, Immunity and Inflammation, Institute for Lung Health, NIHR Respiratory Biomedical Research Unit, University of Leicester, Leicester, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Mitesh Pancholi
2Dept of Infection, Immunity and Inflammation, Institute for Lung Health, NIHR Respiratory Biomedical Research Unit, University of Leicester, Leicester, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Ian D. Pavord
1Dept of Respiratory Medicine, Nuffield Department of Medicine, University of Oxford, Oxford
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Andrew J. Wardlaw
2Dept of Infection, Immunity and Inflammation, Institute for Lung Health, NIHR Respiratory Biomedical Research Unit, University of Leicester, Leicester, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Catherine H. Pashley
2Dept of Infection, Immunity and Inflammation, Institute for Lung Health, NIHR Respiratory Biomedical Research Unit, University of Leicester, Leicester, UK
3Both authors contributed equally
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Christopher E. Brightling
2Dept of Infection, Immunity and Inflammation, Institute for Lung Health, NIHR Respiratory Biomedical Research Unit, University of Leicester, Leicester, UK
3Both authors contributed equally
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Info & Metrics
  • PDF
Loading

Abstract

Bacteria are often isolated in stable chronic obstructive pulmonary disease (COPD). Whether fungi are also commonly present and associated with clinical and pathological features of disease is uncertain. We investigated the frequency of filamentous fungal culture and IgE sensitisation to Aspergillus fumigatus and the relationship to clinical outcomes in COPD subjects.

COPD subjects were recruited to enter a 1-year observational study. Assessments of lung function, allergen testing and sputum analysis for inflammation, bacteria and fungus were undertaken in COPD subjects and healthy smoking and nonsmoking controls.

Filamentous fungi were cultured at baseline in 49% (63 out of 128) of COPD subjects, of which 75% (47 out of 63) were A. fumigatus. Fungus was cultured in three out of 22 controls (two were A. fumigatus). The total sputum cell count and inhaled corticosteroid dosage were significantly increased in COPD patients with a positive filamentous fungal culture at baseline (p<0.05). Sensitisation to A. fumigatus was present in 13% of COPD subjects and was associated with worse lung function (forced expiratory volume in 1 s 39% predicted versus 51% predicted; p=0.01), but not related to filamentous fungal culture.

A. fumigatus sensitisation is related to poor lung function. Positive filamentous fungal culture is a common feature of COPD. The clinical significance of this remains uncertain.

Abstract

A. fumigatus sensitisation links to poor COPD lung function; clinical significance of positive fungal culture is unclear http://ow.ly/qfr5q

Introduction

Chronic obstructive pulmonary disease (COPD) is associated with significant morbidity and mortality [1]. It is characterised by irreversible airflow obstruction [2] with underlying emphysema and small airway obliteration, which co-exist commonly [3, 4]. Airways of patients with COPD are often “colonised” with potential pathogenic microorganisms [5] which give rise to increased airway inflammation [6]. Bacteria and viruses have been implicated as the major cause of COPD exacerbations, whereas the potential role of fungal colonisation and infection in the pathogenesis of COPD is poorly understood. The commonest fungal genus to cause pulmonary-associated fungal infections is Aspergillus [7], with a wide spectrum of syndromes, including saprophytic invasion, allergic disease and invasive aspergillosis [8], often due to Aspergillus fumigatus [7]. Additionally, allergic bronchopulmonary aspergillosis (ABPA) [9–12], found commonly in asthma and cystic fibrosis [13], is increasingly recognised in COPD [14]. Furthermore, sensitisation to A. fumigatus has been found to be associated with poor lung function in severe asthmatics [15]. Impairment in host defence systems in immunocompetent and immunocompromised patients, including those with COPD, is thus likely to promote susceptibility to fungal infections. How this impacts on important clinical outcomes in COPD such as disease severity, inflammation and exacerbations is currently unknown.

We hypothesised that the presence of filamentous fungi in the airways of patients with COPD and sensitisation to A. fumigatus is associated with disease severity, airway inflammation and exacerbations. To study this, we carried out a longitudinal study to investigate fungal culture in patients with COPD during stable state and exacerbations.

Methods

Subjects and measurements

Subjects with COPD diagnosed according to the Global Initiative for Chronic Obstructive Lung Disease (GOLD) guidelines [2] were recruited as part of a larger biomarker-directed randomised controlled study [16]. Subjects with a diagnosis of asthma, active pulmonary tuberculosis or any other clinically relevant lung disease were excluded. All COPD subjects underwent lung function testing including reversibility testing [17]. Sputum was collected for analysis of routine microbiology for potential pathogenic microorganisms (defined as Haemophilus influenzae, Moraxella catarrhalis, Streptococcus pneumoniae, Staphylococcus aureus or Pseudomonas aeruginosa) [18] and mycology [15, 19]. In brief, ∼150 mg of undiluted sputum was inoculated onto potato dextrose agar plates containing chloramphenicol (16 μg·mL−1), gentamicin (4 μg·mL−1) and fluconazole (5 μg·mL−1). Plates were then incubated at 37°C and inspected daily for up to 7 days. A. fumigatus colonies were identified by colony formation and microscopy. PCR sequencing of the large subunit or the internal transcribed spacer region of the nuclear ribosomal operon was used for the detection of other filamentous fungi, as previously described [19].

Sputum was also processed to produce cytospins for assessment of sputum total and differential cell counts [20, 21]. Venous blood was collected for assessment of peripheral blood differential cell counts and serum C reactive protein. Health status and symptom scores were measured using the St George’s Respiratory Questionnaire (University of London, London, UK) [22], the Chronic Respiratory Disease Interviewer-Administered Questionnaire (CRQ) (McMaster University, Hamilton, Canada) [23] and the visual analogue scale (VAS) for the domains of cough, breathlessness, sputum production and sputum purulence [24]. Subjects were seen during stable-state and exacerbation visits; sample collection was performed prior to randomisation and institution of any therapy. Nonsmoking and nonobstructed smoking controls were invited to attend a single study visit, with lung function testing, sputum induction and demographic data collection. Skin-prick testing was used to assess atopy to Dermatophagoides pteronyssinus, dog, cat, grass pollen and to the fungi Alternaria alternata, A. fumigatus, Botrytis cinerea, Cladosporium herbarum and Penicillium chrysogenum (Alk-Abello, Hørsholm, Denmark). Total IgE levels, allergen-specific IgE antibody levels to cat, dog, timothy grass, D. pteronyssinus and A. fumigatus, and A. fumigatus-IgG levels were measured using the ImmunoCap 250 system (Phadia Ltd, Milton Keynes, UK).

The study was approved by the Leicestershire, Northamptonshire and Rutland ethics committee and all subjects gave informed written consent.

Statistical analysis

Statistical analysis was performed using PRISM version 4 (GraphPad, San Diego, CA, USA) and SPSS version 16 (SPSS Inc., Chicago, IL, USA). Parametric and nonparametric data are presented as mean±sem and median (interquartile range) unless otherwise stated. Log-transformed data are presented as geometric mean (95% CI). For comparison of unpaired or paired parametric or nonparametric groups, t-tests, Mann–Whitney U-test and Wilcoxon matched-pairs tests were used. For comparison of three groups or more for parametric and nonparametric variables the ANOVA or Kruskal–Wallis test was used, and the Chi-squared test was used for proportions. Repeatability of A. fumigatus culture was assessed in patients with two stable visits 3 months apart, using the Cohen κ statistic. Logistic regression analysis was used to assess the relationship of the variables of forced expiratory volume in 1 s (FEV1) % predicted, sputum eosinophil count (log-transformed), sputum neutrophil count (log-transformed) and exacerbation frequency with the presence of 1) A. fumigatus-only culture and 2) sensitisation to A. fumigatus using the block entry method. Standard multiple regression analysis was used to assess the relationship of airway inflammation, exacerbation frequency, fungal culture and fungal sensitisation with lung function. Logistic regression goodness-to-fit was performed using the Hosmer–Lemeshow Chi-squared and R-squared (true and pseudo-R2 for multiple and logistic regression, respectively) tests were used to estimate the variance explained by the model. A p-value of <0.05 was taken as the threshold of significance.

Results

Filamentous fungal culture and baseline demographic data were obtained in 128 patients with COPD (89 males and 39 females). The mean FEV1 in the COPD subjects was 48±3% pred. Control data were available in 22 (eight males and 14 females) subjects with a mean (range) age of 58 (41–79) years; mean (range) smoking history of 10 (0–30) pack-years and a mean FEV1 of 116±3% pred. The clinical characteristics of the COPD patients and controls are presented in table 1. A filamentous fungus was isolated in 49% (63 out of 128) of COPD patients and was predominantly Aspergillus or Penicillium species (online supplementary table E1). A. fumigatus was cultured in 37% (47 out of 128) of patients, while identification of any Aspergillus species was present in 42% (55 out of 128) of patients. Pathogenic bacteria (H. influenzae, M. catarrhalis, S. pneumoniae, S. aureus or P. aeruginosa) and A. fumigatus co-culture was found in 14% (18 out of 128) of patients at baseline stable state. The proportion of control subjects that had positive filamentous fungal cultures was significantly lower compared to COPD subjects (14% versus 49%; mean difference 36%, 95% CI 14–48%; p=0.002).

View this table:
  • View inline
  • View popup
Table 1– Clinical characteristics of chronic obstructive pulmonary disease (COPD) subjects and controls

A. fumigatus culture and clinical outcomes

Patients with A. fumigatus were on a higher inhaled corticosteroid dose compared to those who were culture-negative (1628 versus 1389 μg beclomethasone dipropionate equivalent; mean difference 239, 95% CI 0–477; p=0.050). There were no differences in health status, exacerbation frequency or FEV1 % pred in COPD subjects who were A. fumigatus culture-positive compared to those who were A. fumigatus culture-negative (table 2). There was a significant difference in total and percentage sputum neutrophil count, but not in sputum eosinophils in patients with A. fumigatus compared to patients with no fungi or other filamentous fungi (fig. 1). The total sputum neutrophil count was the most independent predictor of A. fumigatus culture, with a sensitivity and specificity of 54% and 76%, respectively (table 3).

View this table:
  • View inline
  • View popup
Table 2– Clinical characteristics of chronic obstructive pulmonary disease subjects according to filamentous fungal status
Figure 1–
  • Download figure
  • Open in new tab
  • Download powerpoint
Figure 1–

a) Percentage and b) total sputum neutrophil counts, and c) percentage sputum eosinophils in patients with Aspergillus fumigatus culture (Af+), other filamentous fungi and no fungi cultured at study entry. Bars represent mean±sem. *: p<0.05.

View this table:
  • View inline
  • View popup
Table 3– Predictors of Aspergillus fumigatus sputum culture in chronic obstructive pulmonary disesase subjects at stable state

Atopy and A. fumigatus

Atopy, defined as a positive skin prick testing and/or elevated allergen-specific antibodies, was found in 34% of COPD patients. Concordance of serum-specific IgE antibodies and skin prick testing to the common allergens, showed a good strength of agreement (κ=0.63, 95% CI 0.49–0.76). Sensitisation to A. fumigatus (positive skin prick test and/or elevated A. fumigatus IgE antibodies) was present in 13% of patients. Sensitisation to A. fumigatus, irrespective of corresponding filamentous fungal culture, was associated with lower lung function (FEV1 39% pred versus 51% pred; mean difference 11%, 95% CI 3–20%; p=0.01) (fig. 2). There were no differences in parameters of airway inflammation, health status or exacerbation frequency in those that were or were not sensitised to A. fumigatus. FEV1 % pred was the best predictor of A. fumigatus sensitisation (table 4).

Figure 2–
  • Download figure
  • Open in new tab
  • Download powerpoint
Figure 2–

Forced expiratory volume in 1 s (FEV1) % predicted categorised according to Aspergillus fumigatus (Af) sensitisation. Bars represent mean±sem.

View this table:
  • View inline
  • View popup
Table 4– Predictors of Aspergillus fumigatus sensitisation in chronic obstructive pulmonary disease subjects at stable state

A. fumigatus colonisation

The repeatability of A. fumigatus culture was examined in 70 subjects at two stable visits 3 months apart. The κ agreement statistic (95% CI) was -0.04 (-0.29–0.21). This was determined to be below that observed by chance alone. Of these patients, 13% and 39% were either A. fumigatus-positive or culture-negative, respectively, at both. Neutrophil or eosinophil systemic and airway inflammatory measures were not different between patients who cultured A. fumigatus, other filamentous fungi and no fungi, neither in the repeated visit, nor in patients who either persistently grew filamentous fungi or never grew fungi on two visits.

A. fumigatus during exacerbations

110 exacerbations with filamentous fungal culture from 80 patients were captured. A positive filamentous fungal culture was found in 38% of all exacerbation events; while 28% of all exacerbation events were culture-positive to A. fumigatus. There was no difference in airway inflammation, change in CRQ, FEV1 or VAS scores between those who cultured A. fumigatus at exacerbation compared to those who did not. Corresponding filamentous fungal and bacterial culture data during exacerbations were available in 79 exacerbation events. Co-culture of A. fumigatus and pathogenic bacteria was observed in 14% (11 out of 79) of exacerbation events. There were 44 and 35 bacteria- and nonbacteria-associated exacerbations of COPD. The acquisition of A. fumigatus was not different between bacteria-associated and nonbacterial-associated exacerbations (20% versus 55%, p=0.07). There was no change from baseline in lung function, health status and symptom scores in bacteria- or nonbacteria-associated exacerbations and the culture of A. fumigatus at the baseline and exacerbation visit (online supplementary tables E2 and E3).

Discussion

Here we report that in subjects with COPD, sensitisation to A. fumigatus was associated with poor lung function. Positive culture of filamentous fungi, especially that of A. fumigatus, was commonly found in the sputum of patients with COPD and was increased compared to controls. However, repeatability of A. fumigatus culture in stable state was poor and the prevalence did not change at exacerbations. The clinical significance of a positive filamentous fungal culture in COPD therefore remains uncertain.

In our study, hypersensitivity to A. fumigatus was detected in 13% of the COPD subjects and was associated with reduced lung function independent of A. fumigatus sputum culture. This is consistent with previously observed findings in patients with severe asthma using the same fungal culture technique [15]. Whether sensitisation to A. fumigatus contributes to the cause of airflow obstruction or is a consequence of a damaged and remodelled airway and thus more likely in subjects with severe COPD is uncertain. In severe asthma the relationship between sensitisation and filamentous fungal culture suggests that persistent colonisation may promote sensitisation. Although we were unable to replicate the finding of colonisation in our study, it remains plausible that sensitisation reflects increased filamentous fungi exposure over time.

Sensitisation to A. fumigatus is a feature of ABPA. Although we did not undertake computed tomography in this study, none of our subjects fulfilled the criteria of Greenberger and co-workers [11, 12] for ABPA. The incomplete fulfilment of these ABPA criteria has also been shown in previous COPD studies [14]. In asthma associated with ABPA and in severe asthma with fungal sensitisation, antifungal therapy has demonstrated clinical benefit, although the magnitude of this effect is small [25–27]. Whether antifungal therapy may be effective in reducing exacerbations and disease progression in COPD patients with filamentous fungal sensitisation remains to be tested.

Colonisation of the airways, defined as “the presence of potentially pathogenic organisms without an associated inflammatory response” is common in patients with COPD, occurring in up to 30% [5]. Using a specialist fungal culture technique, we have shown that the presence of filamentous mould (mainly A. fumigatus) was found in almost half of subjects with COPD, and that neutrophilic airway inflammation was the best predictor of A. fumigatus sputum culture. The presence of A. fumigatus or any filamentous fungal culture was also related to higher doses of inhaled corticosteroids. Immunosuppression from corticosteroid treatment has been associated with invasive aspergillosis and studies have determined that corticosteroid therapy is an independent predictor of invasive aspergillosis in COPD patients in intensive care [28, 29]. Current COPD guidelines advocate the use of inhaled corticosteroids in patients with FEV1 <50% and recurrent exacerbations to reduce the risk of future exacerbations [2]. At present it remains unclear whether there is an inhaled corticosteroid dose–response predisposition to A. fumigatus colonisation in a susceptible cohort or an associated increase in risk of invasive aspergillosis; this requires further study.

Colonisation of Aspergillus in immunocompetent individuals does not fulfil the criteria for definite or probable invasive aspergillosis [30, 31]. However, this definition has focused on filamentous fungal detection from respiratory samples collected on a single episode. There is a paucity of data in the literature examining repeated A. fumigatus culture in COPD subjects at stable state, and even less investigating A. fumigatus during exacerbations. In this study we could not determine repeatability of A. fumigatus culture in subsequent stable visits. However, our study highlights the importance of examining relationships of pathogen and airway inflammation expression in longitudinal studies, and we have aimed to explore the classification of filamentous fungal colonisation in the COPD airway and related this to important clinical outcomes. Although we have been unable to show that there is persistence of A. fumigatus culture in a cohort of patients with repeated visits, emerging knowledge regarding the complex microbiota of the airways in COPD [32] would suggest that the role of filamentous fungi, and in particular A. fumigatus, needs to be further explored in the pathogenesis of COPD. Our study was strengthened by examining filamentous fungal culture in the airways of non-COPD controls, and showed that despite similar atopy rates there was significantly reduced detection of fungal and A. fumigatus culture in control subjects. Although the control group was not matched for age or smoking, the detection of filamentous fungus in the sputum was significantly lower and independent of atopy status. A final concern is whether we have inadvertently included patients with asthma and classed these patients as COPD. However, to reduce this bias a strict exclusion criteria for screening was a current or previous history of asthma, whether self-reported or physician-diagnosed, and used current spirometric diagnostic criteria for COPD as per GOLD guidelines [2]. Therefore, whether our finding of A. fumigatus sensitisation and worsened lung function is related to disease or prolonged exposure needs to be further evaluated in larger studies.

To our knowledge, this is the first study to examine filamentous fungal and A. fumigatus culture rates during exacerbations of COPD. In contrast to our hypothesis, we detected that filamentous fungal culture rates and in particular A. fumigatus was not increased during exacerbations of COPD. Studies have shown that bacterial and fungal interactions include promotion of survival and virulence of fungus, or inhibition of filament formation [33]. Furthermore, the development of bacterial and fungal biofilms may provide a host defence environment which has resistance to antibiotic properties [33]. In this study we found that A. fumigatus culture was not affected by the presence or absence of concomitant bacterial culture; whether interactions between filamentous fungal and bacterial infection during exacerbations are important remains to be fully determined.

In conclusion, we have shown that A. fumigatus in commonly found in the sputum of patients with COPD and that this is irrespective of disease severity. We have also shown that IgE sensitisation to A. fumigatus in COPD subjects is associated with lower lung function and that the detection of A. fumigatus by sputum culture is increased compared to controls but unrelated to exacerbations. However, the clinical significance of fungi in COPD and the response to antifungal therapy remains to be determined and further studies are required.

Acknowledgments

The authors would like to thank all the research volunteers who participated in the study and the following people for their assistance during the study: Michelle Bourne, Beverly Hargadon, Maria Shelley, Amisha Singapuri and Sarah Terry (Dept of Infection, Immunity and Inflammation, Institute for Lung Health, NIHR Respiratory Biomedical Research Unit, University of Leicester, Leicester, UK) and Hemu Patel (Dept of Clinical Microbiology, Leicester Royal Infirmary, University of Leicester Hospitals NHS Trust, Leicester, UK).

Footnotes

  • This article has supplementary material available from www.erj.ersjournals.com

  • Earn CME accreditation by answering questions about this article. You will find these at the back of the printed copy of this issue or online at www.erj.ersjournals.com/misc/cmeinfo.xhtml

  • Support statement: The study was funded by the Medical Research Council (UK), a senior Wellcome Fellowship (C.E. Brightling) and the Midlands Asthma Allergy Research Association. The research was performed in laboratories part funded by the European Regional Development Fund (ERDF 05567). This article presents independent research funded by the National Institute for Health Research (NIHR). The views expressed are those of the authors and not necessarily those of the NHS, the NHR or the Department of Health.

  • Conflict of interest: Disclosures can be found alongside the online version of this article at www.erj.ersjournals.com

  • Received October 11, 2012.
  • Accepted April 10, 2013.
  • ©ERS 2014

References

  1. ↵
    1. Lopez AD,
    2. Shibuya K,
    3. Rao C,
    4. et al
    . Chronic obstructive pulmonary disease: current burden and future projections. Eur Respir J 2006; 27: 397–412.
    OpenUrlFREE Full Text
  2. ↵
    1. Rabe KF,
    2. Hurd S,
    3. Anzueto A,
    4. et al
    . Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary. Am J Respir Crit Care Med 2007; 176: 532–555.
    OpenUrlCrossRefPubMedWeb of Science
  3. ↵
    1. Hogg JC,
    2. Chu F,
    3. Utokaparch S,
    4. et al
    . The nature of small-airway obstruction in chronic obstructive pulmonary disease. N Engl J Med 2004; 350: 2645–2653.
    OpenUrlCrossRefPubMedWeb of Science
  4. ↵
    1. Jeffery PK
    . Structural and inflammatory changes in COPD: a comparison with asthma. Thorax 1998; 53: 129–136.
    OpenUrlCrossRefPubMedWeb of Science
  5. ↵
    1. Sethi S,
    2. Murphy TF
    . Infection in the pathogenesis and course of chronic obstructive pulmonary disease. N Engl J Med 2008; 359: 2355–2365.
    OpenUrlCrossRefPubMedWeb of Science
  6. ↵
    1. O'Donnell R,
    2. Breen D,
    3. Wilson S,
    4. et al
    . Inflammatory cells in the airways in COPD. Thorax 2006; 61: 448–454.
    OpenUrlAbstract/FREE Full Text
  7. ↵
    1. Bulpa P,
    2. Dive A,
    3. Sibille Y
    . Invasive pulmonary aspergillosis in patients with chronic obstructive pulmonary disease. Eur Respir J 2007; 30: 782–800.
    OpenUrlAbstract/FREE Full Text
  8. ↵
    1. Al-Alawi A,
    2. Ryan CF,
    3. Flint JD,
    4. et al
    . Aspergillus-related lung disease. Can Respir J 2005; 12: 377–387.
    OpenUrlPubMed
  9. ↵
    1. Wardlaw A,
    2. Geddes DM
    . Allergic bronchopulmonary aspergillosis: a review. J R Soc Med 1992; 85: 747–751.
    OpenUrlFREE Full Text
    1. Tillie-Leblond I,
    2. Tonnel AB
    . Allergic bronchopulmonary aspergillosis. Allergy 2005; 60: 1004–1013.
    OpenUrlCrossRefPubMedWeb of Science
  10. ↵
    1. Greenberger PA
    . Allergic bronchopulmonary aspergillosis. J Allergy Clin Immunol 1984; 74: 645–653.
    OpenUrlCrossRefPubMedWeb of Science
  11. ↵
    1. Greenberger PA,
    2. Miller TP,
    3. Roberts M,
    4. et al
    . Allergic bronchopulmonary aspergillosis in patients with and without evidence of bronchiectasis. Ann Allergy 1993; 70: 333–338.
    OpenUrlPubMedWeb of Science
  12. ↵
    1. Denning DW
    . Chronic forms of pulmonary aspergillosis. Clin Microbiol Infect 2001; 7: Suppl. 2, 25–31.
    OpenUrlPubMed
  13. ↵
    1. Agarwal R,
    2. Hazarika B,
    3. Gupta D,
    4. et al
    . Aspergillus hypersensitivity in patients with chronic obstructive pulmonary disease: COPD as a risk factor for ABPA? Med Mycol 2010; 48: 988–994.
    OpenUrlAbstract/FREE Full Text
  14. ↵
    1. Fairs A,
    2. Agbetile J,
    3. Hargadon B,
    4. et al
    . IgE sensitization to Aspergillus fumigatus is associated with reduced lung function in asthma. Am J Respir Crit Care Med 2010; 182: 1362–1368.
    OpenUrlCrossRefPubMedWeb of Science
  15. ↵
    1. Bafadhel M,
    2. McKenna S,
    3. Terry S,
    4. et al
    . Blood eosinophils to direct corticosteroid treatment of exacerbations of chronic obstructive pulmonary disease: a randomized placebo-controlled trial. Am J Respir Crit Care Med 2012; 186: 48–55.
    OpenUrlCrossRefPubMedWeb of Science
  16. ↵
    1. Brusasco V,
    2. Crapo R,
    3. Viegi G
    . Coming together: the ATS/ERS consensus on clinical pulmonary function testing. Eur Respir J 2005; 26: 1–2.
    OpenUrlFREE Full Text
  17. ↵
    Health Protection Agency. Investigation of bronchoalveolar lavage, sputum and associated specimens. National Standard Method BSOP 57 Issue 2.3.
  18. ↵
    1. Pashley CH,
    2. Fairs A,
    3. Morley JP,
    4. et al
    . Routine processing procedures for isolating filamentous fungi from respiratory sputum samples may underestimate fungal prevalence. Med Mycol 2012; 50: 433–438.
    OpenUrlAbstract/FREE Full Text
  19. ↵
    1. Pizzichini E,
    2. Pizzichini MM,
    3. Efthimiadis A,
    4. et al
    . Indices of airway inflammation in induced sputum: reproducibility and validity of cell and fluid-phase measurements. Am J Respir Crit Care Med 1996; 154: 308–317.
    OpenUrlCrossRefPubMedWeb of Science
  20. ↵
    1. Pizzichini MM,
    2. Popov TA,
    3. Efthimiadis A,
    4. et al
    . Spontaneous and induced sputum to measure indices of airway inflammation in asthma. Am J Respir Crit Care Med 1996; 154: 866–869.
    OpenUrlCrossRefPubMedWeb of Science
  21. ↵
    1. Jones PW,
    2. Quirk FH,
    3. Baveystock CM,
    4. et al
    . A self-complete measure of health status for chronic airflow limitation. The St. George's Respiratory Questionnaire. Am Rev Respir Dis 1992; 145: 1321–1327.
    OpenUrlCrossRefPubMedWeb of Science
  22. ↵
    1. Guyatt G
    . Measuring health status in chronic airflow limitation. Eur Respir J 1988; 1: 560–564.
    OpenUrlAbstract/FREE Full Text
  23. ↵
    1. Brightling CE,
    2. Monterio W,
    3. Green RH,
    4. et al
    . Induced sputum and other outcome measures in chronic obstructive pulmonary disease: safety and repeatability. Respir Med 2001; 95: 999–1002.
    OpenUrlCrossRefPubMedWeb of Science
  24. ↵
    1. Wark PA,
    2. Gibson PG,
    3. Wilson AJ
    . Azoles for allergic bronchopulmonary aspergillosis associated with asthma. Cochrane Database Syst Rev 2004; 3: CD001108.
    OpenUrlPubMed
    1. Denning DW,
    2. O'Driscoll BR,
    3. Powell G,
    4. et al
    . Randomized controlled trial of oral antifungal treatment for severe asthma with fungal sensitization: The Fungal Asthma Sensitization Trial (FAST) study. Am J Respir Crit Care Med 2009; 179: 11–18.
    OpenUrlCrossRefPubMedWeb of Science
  25. ↵
    1. Stevens DA,
    2. Schwartz HJ,
    3. Lee JY,
    4. et al
    . A randomized trial of itraconazole in allergic bronchopulmonary aspergillosis. N Engl J Med 2000; 342: 756–762.
    OpenUrlCrossRefPubMedWeb of Science
  26. ↵
    1. Ader F,
    2. Nseir S,
    3. Le Berre R,
    4. et al
    . Invasive pulmonary aspergillosis in chronic obstructive pulmonary disease: an emerging fungal pathogen. Clin Microbiol Infect 2005; 11: 427–429.
    OpenUrlCrossRefPubMedWeb of Science
  27. ↵
    1. McEvoy CE,
    2. Niewoehner DE
    . Adverse effects of corticosteroid therapy for COPD. A critical review. Chest 1997; 111: 732–743.
    OpenUrlCrossRefPubMedWeb of Science
  28. ↵
    1. Vandewoude KH,
    2. Blot SI,
    3. Depuydt P,
    4. et al
    . Clinical relevance of Aspergillus isolation from respiratory tract samples in critically ill patients. Crit Care 2006; 10: R31.
    OpenUrlCrossRefPubMed
  29. ↵
    1. Lucena P,
    2. Barberán J,
    3. Eroles G,
    4. et al
    . Significance of lower respiratory tract cultures yielding Aspergillus spp. growth in a hospital without transplant patients. Rev Esp Quimioter 2010; 23: 190–195.
    OpenUrlPubMed
  30. ↵
    1. Hilty M,
    2. Burke C,
    3. Pedro H,
    4. et al
    . Disordered microbial communities in asthmatic airways. PLoS One 2010; 5: e8578.
    OpenUrlCrossRefPubMed
  31. ↵
    1. Wargo MJ,
    2. Hogan DA
    . Fungal–bacterial interactions: a mixed bag of mingling microbes. Curr Opin Microbiol 2006; 9: 359–364.
    OpenUrlCrossRefPubMedWeb of Science
View Abstract
PreviousNext
Back to top
View this article with LENS
Vol 43 Issue 1 Table of Contents
European Respiratory Journal: 43 (1)
  • Table of Contents
  • Table of Contents (PDF)
  • About the Cover
  • Index by author
Email

Thank you for your interest in spreading the word on European Respiratory Society .

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Aspergillus fumigatus during stable state and exacerbations of COPD
(Your Name) has sent you a message from European Respiratory Society
(Your Name) thought you would like to see the European Respiratory Society web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Print
Citation Tools
Aspergillus fumigatus during stable state and exacerbations of COPD
Mona Bafadhel, Susan Mckenna, Joshua Agbetile, Abbie Fairs, Dhananjay Desai, Vijay Mistry, Joseph P. Morley, Mitesh Pancholi, Ian D. Pavord, Andrew J. Wardlaw, Catherine H. Pashley, Christopher E. Brightling
European Respiratory Journal Jan 2014, 43 (1) 64-71; DOI: 10.1183/09031936.00162912

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero

Share
Aspergillus fumigatus during stable state and exacerbations of COPD
Mona Bafadhel, Susan Mckenna, Joshua Agbetile, Abbie Fairs, Dhananjay Desai, Vijay Mistry, Joseph P. Morley, Mitesh Pancholi, Ian D. Pavord, Andrew J. Wardlaw, Catherine H. Pashley, Christopher E. Brightling
European Respiratory Journal Jan 2014, 43 (1) 64-71; DOI: 10.1183/09031936.00162912
del.icio.us logo Digg logo Reddit logo Technorati logo Twitter logo CiteULike logo Connotea logo Facebook logo Google logo Mendeley logo
Full Text (PDF)

Jump To

  • Article
    • Abstract
    • Abstract
    • Introduction
    • Methods
    • Results
    • Discussion
    • Acknowledgments
    • Footnotes
    • References
  • Figures & Data
  • Info & Metrics
  • PDF

Subjects

  • COPD and smoking
  • Respiratory infections and tuberculosis
  • Tweet Widget
  • Facebook Like
  • Google Plus One

More in this TOC Section

Original Article

  • Lung volumes and survival in chronic lung allograft dysfunction
  • EBUS-guided cryobiopsies in peripheral pulmonary lesions
  • Safety of formoterol in asthma clinical trials
Show more Original Article

COPD

  • Lung volume reduction surgery versus endobronchial valves
  • Long-acting bronchodilator combination therapy and cardiovascular events in COPD
  • Sensitisation to recombinant A. fumigatus allergens and outcomes in COPD
Show more COPD

Related Articles

Navigate

  • Home
  • Current issue
  • Archive

About the ERJ

  • Journal information
  • Editorial board
  • Press
  • Permissions and reprints
  • Advertising

The European Respiratory Society

  • Society home
  • myERS
  • Privacy policy
  • Accessibility

ERS publications

  • European Respiratory Journal
  • ERJ Open Research
  • European Respiratory Review
  • Breathe
  • ERS books online
  • ERS Bookshop

Help

  • Feedback

For authors

  • Instructions for authors
  • Publication ethics and malpractice
  • Submit a manuscript

For readers

  • Alerts
  • Subjects
  • Podcasts
  • RSS

Subscriptions

  • Accessing the ERS publications

Contact us

European Respiratory Society
442 Glossop Road
Sheffield S10 2PX
United Kingdom
Tel: +44 114 2672860
Email: journals@ersnet.org

ISSN

Print ISSN:  0903-1936
Online ISSN: 1399-3003

Copyright © 2023 by the European Respiratory Society